@sponlinecoaching's TRT steroid claims, fact-checked

What did @sponlinecoaching actually say?

The creator's core argument is this: testosterone is technically a steroid hormone, but TRT is meaningfully different from "being on steroids" because TRT aims for physiological levels while anabolic cycles push 200 to 1,000 percent above what the body naturally produces. They framed it as a dose-based distinction, not a chemical one, which is actually a defensible position worth examining carefully.

They said TRT should bring levels "into a normal range, an upper normal range" rather than "super physiological." That framing does a lot of work. Whether that distinction holds up scientifically depends entirely on how TRT is actually prescribed and monitored in practice, not just how it's described in theory.

Does the science back this up?

Partially, yes. The dose-response framework the creator describes is real and well-documented. Bhasin et al. (2001, New England Journal of Medicine) showed in a landmark dose-escalation study that anabolic effects like muscle gain and fat loss scale with testosterone dose, with supraphysiological levels producing significantly greater changes than eugonadal replacement. The distinction between replacement and supraphysiological use is not just semantic.

However, the "1,000 percent" framing for anabolic cycles deserves scrutiny. A natural testosterone level might sit around 400 to 700 ng/dL for an adult male. Common bodybuilding doses of testosterone alone (400 to 600 mg per week of testosterone cypionate) typically produce serum levels in the 1,500 to 2,500 ng/dL range, which is roughly 3 to 6 times physiological, not 10 to 20 times. The "up to 1,000 percent" claim appears inflated when applied to testosterone specifically, though it may apply to equivalent androgenic potency across multiple compounds stacked together.

What did they get wrong (or right)?

They got the conceptual framework mostly right. Testosterone is a steroid hormone, and the distinction between replacement dosing and anabolic dosing is clinically meaningful. Credit where it's due.

What they got wrong, or at least imprecise: the "1,000 percent" figure. If we're talking total androgenic load across a complex cycle including trenbolone, nandrolone, and testosterone together, the equivalent androgenic burden could approach those numbers. But presented without that context, it's misleading. A listener will assume this applies to testosterone alone, which it generally doesn't.

There's also a real-world complication the creator skips entirely. TRT as prescribed in clinical settings targets roughly 400 to 900 ng/dL. But "optimization" clinics, concierge practices, and online TRT platforms frequently prescribe doses that produce levels of 1,000 to 1,500 ng/dL. Mulhall et al. (2018, Journal of Urology) noted that many men on TRT are maintained at levels well above the clinical normal range. So the clean line between TRT and steroid use gets blurry in practice.

What should you actually know?

The dose-based distinction is real, but it's not as clean as this video implies. Testosterone is testosterone regardless of the prescription label on the vial. The clinical difference between TRT and anabolic use comes down to intent, monitoring, and actual serum levels achieved, not simply whether someone has a prescription.

A few things worth knowing:

• Normal total testosterone reference ranges vary by lab, but most guidelines (Endocrine Society, 2018) define hypogonadism as levels below 300 ng/dL on two morning measurements.
• TRT does carry real risks at any dose, including erythrocytosis (elevated red blood cell count), suppression of natural testosterone production, and effects on fertility. Ramasamy et al. (2015, Fertility and Sterility) documented significant negative effects on sperm production even at therapeutic doses.
• The creator's framing that supraphysiological use "comes with a slew of other health side effects" is accurate in direction, but TRT at upper-normal or above-normal levels also carries cardiovascular and hematological risks that shouldn't be dismissed. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) found non-inferiority on major cardiac events for TRT in hypogonadal men with cardiovascular risk, but the population matters.
• The creator is selling coaching services, which is worth noting when evaluating how they frame TRT as a benign, clearly-delineated intervention.